Paxlovid-Induced Tacrolimus Toxicity in the Treatment of COVID-19: A Case Report

Paxlovid(TM) (nirmaltrelvir/ritonavir) received emergency use authorization from the Food and Drug Administration (FDA) in December 2021 to treat coronavirus disease 2019 (COVID-19). Given the actions of Paxlovid on cytochrome P450-3A4 (CYP3A4) enzymes, it is imperative to check for potential drug-d...

Descripción completa

Detalles Bibliográficos
Autores principales: Michael, Stephanie, Heilbronner, Rachel, Lloyd, Christopher M, Levitin, Howard W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Emergency Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046481/
https://www.ncbi.nlm.nih.gov/pubmed/36999105
http://dx.doi.org/10.7759/cureus.35489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046481/
https://www.ncbi.nlm.nih.gov/pubmed/36999105
http://dx.doi.org/10.7759/cureus.35489

Ejemplares similares